Mounjaro Dosage: Weekly Schedule, Chart, and Maximum Dose

The standard Mounjaro dosage starts at 2.5 mg injected once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg once weekly. Mounjaro (tirzepatide) is a prescription medicine, so the exact dose and the speed of increases should be set by a healthcare provider who knows your history.

Mounjaro is FDA-approved for adults with type 2 diabetes, and it is also prescribed off-label for weight loss. The medication is sold as single-dose pens in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

Standard Mounjaro Dosage Schedule, Step by Step

Mounjaro is titrated, which means the dose is raised slowly so the body can adjust and gastrointestinal side effects stay manageable. A typical schedule follows a fixed cadence:

1. Weeks 1–4: 2.5 mg once weekly. This is a starter dose and is generally not expected to control blood sugar or drive weight loss on its own.
2. Weeks 5–8: 5 mg once weekly, if the 2.5 mg step was tolerated.
3. Weeks 9–12: 7.5 mg once weekly.
4. Weeks 13–16: 10 mg once weekly.
5. Weeks 17–20: 12.5 mg once weekly.
6. Week 21 and beyond: 15 mg once weekly, which is the maximum labeled dose.

Not everyone needs to reach 15 mg. Many clinicians hold at the lowest dose that produces the desired effect, and 5 mg, 7.5 mg, or 10 mg are common maintenance doses. A dose can also be paused or stepped back down when side effects are hard to tolerate.

Mounjaro Dosage Chart

The following mounjaro dosage chart reflects the FDA-labeled titration for adults. The timing is a general guide rather than a rule, since a provider may move faster or slower depending on tolerability and treatment goals.

How to Inject Mounjaro Correctly

A mounjaro injection dosage is given subcutaneously, meaning just under the skin, once every 7 days. The injection can be given at any time of day, with or without food, but it works best to pick one consistent day each week.

• Inject into the abdomen, thigh, or upper arm, and rotate the site each week.
• Use a fresh single-dose pen for every injection, and never share a pen.
• Check the liquid before injecting; it should be clear and colorless. Do not use a pen if the solution is cloudy or contains particles.
• Store pens in the refrigerator and let one warm to room temperature before use if cold injections sting.

If a dose is missed, it can usually be taken within 4 days (96 hours) of the scheduled day. Otherwise, skip the missed dose and resume the normal weekly schedule. Doubling up on doses is not safe.

Mounjaro Weight Loss Dosage vs. the Zepbound Dose Schedule

Tirzepatide is marketed under two brand names, and the active drug is identical in both. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in adults who meet specific criteria. The Zepbound dose schedule uses the same 2.5 mg starting dose and the same 2.5 mg step increases up to 15 mg weekly.

Mounjaro for weight loss is an off-label use, which means the FDA has not approved that specific indication for this brand name. Off-label prescribing is legal and common, but it should still be supervised by a licensed clinician.

Compounded "Tirz" Dosing: Why the Numbers Get Confusing

People searching for a tirz dosage chart are often looking at compounded tirzepatide rather than a brand-name pen. Compounded tirzepatide is not FDA-approved, and compounded products are not reviewed by the FDA for safety, effectiveness, or quality.

A listing described as tirz 30mg usually refers to the total amount of drug in a vial, not a single 30 mg dose. Likewise, a tirz 10mg label may mean 10 mg of powder in a vial or a 10 mg weekly dose, depending on the pharmacy. Confusing those two numbers can lead to a serious dosing error, so the concentration on the vial and the prescribed dose should always be confirmed with a pharmacist.

Missed Doses, Side Effects, and Safety

The most common side effects of tirzepatide are nausea, vomiting, diarrhea, constipation, and reduced appetite, and they tend to be worst right after a dose increase. Eating smaller meals, avoiding greasy or very sweet foods, and staying hydrated can help.

Serious but rare risks include pancreatitis, gallbladder problems, severe hypoglycemia when combined with insulin or sulfonylureas, and a boxed warning for thyroid C-cell tumors observed in animal studies. Mounjaro is not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Contact a healthcare professional right away if you experience severe or persistent abdominal pain, signs of an allergic reaction, or vision changes. Do not adjust your dose on your own.

How Mounjaro Dosing Compares with Other Injectables People Research

Anyone weighing reta vs mounjaro dosage should know that retatrutide is an investigational drug and is not FDA-approved for any use, while tirzepatide has an approved label and a defined titration schedule.

Other injectables use entirely different dosing logic. A pt-141 dosage for women, for example, is measured in micrograms and used as needed rather than on a fixed weekly schedule, and a bpc-157 dosage chart by weight is not standardized because BPC-157 has no approved human dosing. AOD-9604 is another research peptide with a separate protocol; an aod 9604 dosage is typically described in micrograms per kilogram or as a fixed daily amount, and none of these compounds are FDA-approved for human use.

Tirzepatide dosing is not one-size-fits-all, and the right plan depends on your diagnosis, tolerability, and treatment response. Ask your prescriber before making any change to your mounjaro dosage.